Vertex Pharmaceuticals, Inc.

James Daniel Frantz

Jian Jim Wang

Albert Charles Pierce

Francois Maltais

Robert J Davies

Huai Gao

Emanuele Perola

Jingrong Cao

Anne-Laure Grillot

Yusheng Liao

Wenxin Gu

James A Henderson

David Messersmith

Ronald Lee Grey, Jr

Philip N Collier

Michael Paul DeNinno

Sanjay Shivayogi Magavi

Joshua Syken

Adrianne Lynn Kolpak

Elizabeth Jin-Sun Ryu

Meghan Elise Cockerill

Elisabeth Doyle

Brian Anthony Goldman

Chao Lin

Yi Zhou

Ann Dak-Yee Kwong

Raul Eduardo Krauss

Tara Lynn Kieffer

Douglas John Bartels

Judith A Lippke

Eileen Z Zhang

James C Sullivan

Raul Eduardo Krauss Irarrazaval

Benjamin Shames

Sheila Seepersaud

The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases:  The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles for the treatment of demyelinating dieases

The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles for the treatment of Demyelinating Diseases

A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO:12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.

Methods for amplifying hepatitis C virus nucleic acids

Growing community of inventors

Belmont, MA, United States of America

James Daniel Frantz